$PURE “Lion Stock Alerts” Promoter Rank: 20/22 PURE Bioscience Newsletter 7:36:11 AM May 11, 2022

on May 11, 2022 Newsletters and Tags: , , , , , , , , , , with 0 comments

Overall Perfomance for "Lion Stock Alerts"

The following three charts can be used by potential investors to gauge the performance of "Lion Stock Alerts":


2 out of 14 campaigns closed down on first day


4 out of 14 campaigns closed up on first day


8 out of 14 campaigns had no net effect

PURE Promotional Newsletter

The following is a newsletter released by "Lion Stock Alerts" promoting PURE Bioscience


The following newsletter has not been verified for accuracy or completeness.


Don't Want Anymore Emails


New Alert BioSig Technologies, Inc. NASDAQ BSGM

Technology is changing the way we experience healthcare.

Bioelectronic medicine is a new approach to treating and diagnosing disease and injury and BSGM could be on the frontlines of that change.

BSGM is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals.

This new field uses device technology to read and modulate the electrical activity within the bodys nervous system, opening new doors to real-time diagnostics and treatment options for patients.

One of the exciting aspects of bioelectronic medicine is its potential to supplement and even replace drugs, including their cost and often debilitating side effects.

Bioelectronic medicine could deliver treatment breakthroughs for many diseases that currently have a high level of unmet need.

By providing clearer biomedical signals, the companys advanced signal processing capabilities can help clinicians better understand and change patterns to treat, or even prevent diseases.

The companys first product, the PURE EPtm System, is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology EP procedures in an EP laboratory.

The PURE EPTM System is an FDA 510k cleared non-invasive class II device that aims to enhance physician workflow and increase procedural efficiency and efficacy in cardiac electrophysiology.

The PURE EP System is being used in all types of arrhythmia cases, including atrial fibrillation, ventricular tachycardia, and atrial flutter.

As the company further explains

Clinical data acquired by the PURE EPTM System in a multi-center study at Texas Cardiac Arrhythmia Institute at St. David's Medical Center, Mayo Clinic Jacksonville, and Massachusetts General Hospital was recently published in the Journal of Cardiovascular Electrophysiology and is available electronically with open access via the Wiley Online Library.

Study results showed 93% consensus across the blinded reviewers with a 75% overall improvement in intracardiac signal quality and confidence in interpreting PURE EP signals over conventional sources.

Furthermore, To date, 75 physicians have completed more than 2,200 patient cases with the PURE EPTM System.

In addition, the company has announced multiple developments over the past few months.

Earlier this year, the company announced

BioSig Awarded US Patent Claims for its PURE EP Noise-Filtering Technology

Here are the highlights from this press release

Claims address computer-implemented systems and methods for filtering noise from input cardiac signals using its PURE EP technology

The Company now has 49 issued or allowed worldwide patents covering its novel technology for arrhythmia care

Here are the companys comments from this press release

We are pleased to announce this newest patent allowance which demonstrates the clinical significance of our PURE EP System in filtering noise from complex signals in the EP setting, commented Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies, Inc. We believe we have the leading patent-protected solution for providing superior intracardiac signal information to electrophysiologists during catheter ablation procedures across all types of cardiac arrhythmias.

In March, the company announced

BioSig Technologies, Inc. Appoints John Sieckhaus as Chief Operating Officer

Mr. Sieckhaus brings to the Company 30 years in the healthcare industry, including 21 years at St. Jude Medical and Abbott Laboratories NYSE ABT. During his tenure with St. Jude Medical, Mr. Sieckhaus held commercial leadership positions of rising responsibility, including U.S. National Sales Leader, Senior Vice President General Manager when he led sales and customer relationship management activities in the United States across all cardiovascular product lines.

Mr. Sieckhaus's experience in building and leading high-performance teams, in addition to integrating multiple new and novel technologies and introducing them commercially, led to significant revenue growth for St. Jude Medical over his career. Most recently, Mr. Sieckhaus held the position of Vice President Field Clinical Affairs for Abbott for the United States and CALA, where he created a world-class field clinical and monitoring team to support clinical trials across multiple business units within Abbott's Cardiovascular portfolio. Mr. Sieckhaus holds a Bachelor of Science degree in Biomedical Engineering from Johns Hopkins University.

Here are some of the comments from this press release

I am very excited to join this team and look forward to building upon the foundation of the PURE EP system and its capabilities. Focusing in the area of electrophysiology by providing better solutions in identifying and treating complex arrhythmias for our clinical customers and patients will be extremely rewarding, commented Mr. Sieckhaus

We are pleased to welcome John to the team as we build toward a national rollout of our leading product, PURE EP . John's leadership experience in the electrophysiology space and his impressive track record in capturing and growing market share in the U.S. is well-aligned with our mission to bring our signal processing technology to as many hospitals as possible in the coming years. John will join Gray Fleming in helping run and grow our business while attracting additional talent to the Company, commented Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc.

Moreover, the company also announced

BioSig Technologies, Inc. Announces $3 Million Financing with Family Office

BioSig intends to use the net proceeds from the offering to fund working capital and continue commercialization activities related to the PURE EP System. This funding and its existing capital should provide sufficient operating capital for BioSig to execute its current business plan.

In addition, the company also announced

BioSig Technologies, Inc. Partners with Summit Blue Capital to Provide Equipment Leasing Services

The leasing and finance program provides a non-recourse financial solution for PURE EP to improve purchase flexibility for U.S. hospitals

As the company further explained

We believe that partnering with Summit Blue Capital will have considerable benefits to our commercial plans. We intend to take advantage of the Summit teams expertise, flexibility, and financial solutions as a leasing partner, said Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc. Summit Blue Capital came highly recommended by one of the largest money center U.S. financial institutions. We believe this relationship will help take friction out of the sales cycle and advance our timeline while allowing BioSig to get paid up front per installation. The team at Summit Blue Capital is expected to also help us launch a subscription-based revenue model for our software.


BioSig has made significant improvements to the EP market, and they have a unique technology offering with their PURE EP, said Adam Drill, President of Summit Blue Capital. Summit Blue Capital is excited to partner with BioSig and execute on a strategic financing and leasing program that we believe will benefit their customer roll out and help position them as a leader in medical technology. We look forward to helping each other and building a solid foundation for the future.

In April, the company presented at NobleCon18 Capital Markets Conference and most recently, the company presented at Heart Rhythm 2022 where it featured its newly released PURE EPTM NOVA-5 Software.

Enhanced with NOVA-5 Software, the PURE EPTM System delivers a new standard in signal processing, offering greater customization and smarter workflows.

As the company further explained in its press release

Heart Rhythm 2022 is a hub for innovation and discoveries in medicine. The event serves as a platform for innovators to create and cultivate collaborative discussions with domestic and international leaders across the field of cardiac arrhythmia. This years event will feature over 250 expert-led sessions, education, ground-breaking science, and game-changing innovations.

In addition, just this morning, the company announced

BioSig Technologies, Inc. Issues Shareholder Letter with Corporate Update on Recent Achievements

BSGM could be in a position to experience increased growth.

Make sure to do your own due diligence.

Sources , , , , , , , , , , , , ,

Happy Trading


Note We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.



You should read and understand this disclaimer in its entirety before joining the website or emailblog list of LionStockAlerts.com the Publisher. The information collectively the Advertisement disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, andor losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission the SEC at www.sec.gov the Financial Industry Regulatory Authority the FINRA at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.govconsumercyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial andor legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

Owners and operators of the Publisher have been compensated twenty five thousand dollars by bank wire transfer on 42922 for the distribution of this advertisement about BSGM dated 51122. Previously, owners and operators of the Publisher have been compensated twenty two thousand five hundred dollars by bank wire transfer on 121021 for the distribution of a prior advertisement about BSGM. Previously, owners and operators of the Publisher have been compensated twenty five thousand dollars by bank wire transfer on 111521 for the distribution of a prior advertisement about BSGM. Previously, owners and operators of the Publisher have been compensated eleven thousand five hundred dollars by bank wire transfer on 11421 for the distribution of a prior advertisement about BSGM. Previously, owners and operators of the Publisher have been compensated twenty five thousand dollars by bank wire transfer on 62321 for the distribution of a prior advertisement about BSGM. Prior to the past year, at the time of publication, we disclosed our compensation for the distribution of advertisements about BSGM. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time.

You are receiving this reportrelease because you subscribed to receive it at our website or through a third-party site. All our newsletters include an unsubscribe link, and you can remove yourself at any time from our newsletters by clicking on that unsubscribe link. You can also contact us at infoLionStockAlerts.com to change your information at any time. By your subscription to our profiles, the viewing of this profile andor use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link

www.LionStockAlerts.comDisclaimer and www.LionStockAlerts.comPrivacy-Policy

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of 1 a client company, 2 the party issuing or preparing the information for the company, or 3 other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated reportrelease or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.

Our records indicate that . requested and confirmed to be added to LionStockAlerts.com on July 23, 2019.

6020 Bent Pine Drive
Orlando FL 32828